- Home
- PRCH vs AVIR Comparison
PRCH vs AVIR Comparison
Compare PRCH & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRCH | AVIR |
|---|---|---|
| Founded | 2012 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 753.7M | 450.9M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PRCH | AVIR |
|---|---|---|
| Price | $7.20 | $5.93 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 2 |
| Target Price | ★ $18.00 | $8.00 |
| AVG Volume (30 Days) | ★ 1.0M | 475.6K |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 90.91 | 3.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $482,414,000.00 | $351,367,000.00 |
| Revenue This Year | $3.89 | N/A |
| Revenue Next Year | $16.80 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.18 | N/A |
| 52 Week Low | $4.65 | $2.46 |
| 52 Week High | $19.44 | $6.45 |
Technical Indicators
Market Signals| Indicator | PRCH | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 45.82 | 62.91 |
| Support Level | $6.54 | $3.33 |
| Resistance Level | $8.29 | $6.45 |
| Average True Range (ATR) | 0.45 | 0.29 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 41.08 | 73.63 |
Price Performance
Historical ComparisonAbout PRCH Porch Group Inc.
Porch Group Inc is a vertical software company reinventing the home services and insurance industries. It has four reportable segments: Insurance Services, Software & Data, Consumer Services, and Corporate. The majority of revenue is from the Insurance segment. The Insurance Services segment manages and operates the Reciprocal, providing services related, but not limited, to underwriting, policy renewal, risk management, insurance portfolio management, financial management, and setting investment guidelines in exchange for commissions and fees.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.